p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma

Molecular Cancer Therapeutics
Jiyu GuanSam Okret

Abstract

Acquired resistance to cancer drugs is common, also for modern targeted drugs like the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, a new drug approved for the treatment of the highly aggressive and relapsing mantle cell lymphoma (MCL). The tumor microenvironment often impacts negatively on drug response. Here, we demonstrate that stromal cells protect MCL cells from ibrutinib-induced apoptosis and support MCL cell regrowth after drug removal by impairing ibrutinib-mediated downregulation of PI3K/AKT signaling. Importantly, the stromal cell-mediated ibrutinib resistance was overcome in vitro by inhibiting AKT activity using the PI3K catalytic p110α subunit-specific inhibitor BYL719. This was seen both for MCL cell lines and primary MCL cells. Furthermore, inhibition of p110α activity by BYL719 potentiated the ability of ibrutinib to inhibit MCL tumor growth in vivo in a mouse xenograft model. The stromal cell-mediated ibrutinib resistance was found to be due to a direct interaction with MCL cells and involves the integrin VLA-4, as disrupting stromal cell-MCL cell interaction using a VLA-4 blocking antibody abrogated the ibrutinib resistance. This suggests that combined treatment with ibrutinib and a p110α inhibitor, alter...Continue Reading

References

Jun 29, 2004·Molecular Immunology·Joseph M Dal PortoJohn Cambier
May 10, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Leonard D ShultzRupert Handgretinger
Sep 3, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amanda PsyrriTheofanis Economopoulos
Oct 16, 2009·Annual Review of Immunology·Tomohiro KurosakiYoshihiro Baba
Sep 5, 2012·Cell Research·Oakley C Olson, Johanna A Joyce
Mar 2, 2013·Nature Reviews. Drug Discovery·Douglas W McMillinConstantine S Mitsiades
May 15, 2013·Proceedings of the National Academy of Sciences of the United States of America·Barbara Garmy-SusiniJudith Varner
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
Jun 25, 2014·British Journal of Haematology·Jiao MaY Lynn Wang
Jul 11, 2014·Nature Reviews. Cancer·David W Scott, Randy D Gascoyne
Apr 11, 2015·British Journal of Haematology·Shuang Q ZhangYue Lynn Wang
Jun 20, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sarah E M HermanAdrian Wiestner
Oct 2, 2015·Therapeutic Advances in Hematology·Deborah M Stephens, Stephen E Spurgeon
Jan 14, 2016·Future Oncology·David L Tucker, Simon A Rule
Jan 15, 2016·Blood·Peter MartinKristie A Blum
Mar 5, 2016·Oncotarget·Gergely TalaberSam Okret
Apr 19, 2017·Nature Communications·Xiaohong ZhaoJianguo Tao

❮ Previous
Next ❯

Citations

Jun 18, 2020·Cancers·Gaël Roué, Brigitte Sola
Oct 16, 2021·Hematological Oncology·Haoran WangKeshu Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.